Showing results (2131-2140 of 2,215) with videos related to

Sort By:
Pageof 222
Nature Medicine|May 24, 2011
Lrp5 functions in bone to regulate bone massYajun Cui, Paul J Niziolek, Bryan T MacDonald, et al.
American Journal of Human Genetics|October 7, 2025
Distinguishing syndromic and nonsyndromic cleft palate through analysis of protein-altering de novo variants in 818 triosKelsey R Robinson, Sarah W Curtis, Justin E Paschall, et al.
Nature Communications|June 29, 2022
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaJosh N Vo, Yi-Mi Wu, Jeanmarie Mishler, et al.
Free Radical Biology & Medicine|June 4, 2018
ERCC1-deficient cells and mice are hypersensitive to lipid peroxidationJolanta Czerwińska, Małgorzata Nowak, Patrycja Wojtczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal CancerRobert W Lentz, Tyler J Friedrich, Patrick J Blatchford, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Cancer Discovery|November 14, 2024
The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint BlockadeYi Bao, Gabriel Cruz, Yuping Zhang, et al.
Journal of Autoimmunity|November 6, 2003
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationRobert B Nussenblatt, Darby J S Thompson, Zhuqing Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.
Pageof 222